• +1-646-491-9876
    • +91-20-67278686

    Search

    Malignant Pleural Effusion - Pipeline Review, H1 2017

    Malignant Pleural Effusion - Pipeline Review, H1 2017

    • Report Code ID: RW0001709464
    • Category Pharmaceuticals
    • No. of Pages 32
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Malignant Pleural Effusion - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H1 2017, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.

    Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 3 respectively.

    Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory) .
    - The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Malignant Pleural Effusion - Overview
    Malignant Pleural Effusion - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Malignant Pleural Effusion - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Malignant Pleural Effusion - Companies Involved in Therapeutics Development
    Advantagene Inc
    Biogen Inc
    Genelux Corp
    Shenzen SiBiono GeneTech Co Ltd
    Malignant Pleural Effusion - Drug Profiles
    BG-00001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Malignant Pleural Effusion and Solid Tumors - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate p53 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GLONC-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    methotrexate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Malignant Pleural Effusion - Dormant Projects
    Malignant Pleural Effusion - Product Development Milestones
    Featured News & Press Releases
    May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
    Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec
    May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting
    Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Malignant Pleural Effusion, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Malignant Pleural Effusion - Pipeline by Advantagene Inc, H1 2017
    Malignant Pleural Effusion - Pipeline by Biogen Inc, H1 2017
    Malignant Pleural Effusion - Pipeline by Genelux Corp, H1 2017
    Malignant Pleural Effusion - Pipeline by Shenzen SiBiono GeneTech Co Ltd, H1 2017
    Malignant Pleural Effusion - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Malignant Pleural Effusion, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advantagene Inc
    Biogen Inc
    Genelux Corp
    Shenzen SiBiono GeneTech Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//malignant-pleural-effusion-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//malignant-pleural-effusion-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//malignant-pleural-effusion-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments